Radiat Oncol J.  2016 Dec;34(4):250-259. 10.3857/roj.2016.02033.

Radiotherapy and immune checkpoint blockades: a snapshot in 2016

• Koo T
• Kim IA

• KMID: 2366045
• DOI: http://doi.org/10.3857/roj.2016.02033

Abstract

Immune checkpoint blockades including monoclonal antibodies (mAbs) of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and programmed death-ligand 1 (PD-L1) have been emerged as a promising anticancer therapy. Several immune checkpoint blockades have been approved by US Food and Drug Administration (FDA), and have shown notable success in clinical trials for patients with advanced melanoma and non-small cell lung cancer. Radiotherapy is a promising combination partner of immune checkpoint blockades due to its potent pro-immune effect. This review will cover the current issue and the future perspectives for combined with radiotherapy and immune checkpoint blockades based upon the available preclinical and clinical data.

Keyword

Radiotherapy; Immune checkpoint blockades; Cytotoxic T-lymphocyte antigen-4; Programmed cell death 1 receptor

MeSH Terms

Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Humans
Melanoma
Programmed Cell Death 1 Receptor
Radiotherapy*
T-Lymphocytes, Cytotoxic
United States Food and Drug Administration
Antibodies, Monoclonal
Programmed Cell Death 1 Receptor